Treating Apnea of Prematurity

Area of Science:

• Neonatology
• Pediatric Respiratory Medicine

Background:

• Apnea of prematurity (AOP) is a common condition in premature infants, stemming from immature respiratory control.
• AOP can lead to hypercapnia and increases the risk of neonatal morbidity and mortality.
• The long-term consequences of AOP and its treatments are not well-understood.

Purpose of the Study:

• To review the current understanding of apnea of prematurity.
• To discuss the available treatment options and their associated safety concerns.
• To highlight the uncertainties regarding long-term outcomes and the role of AOP in preterm infant mortality.

Main Methods:

• Literature review of existing studies on apnea of prematurity.
• Analysis of treatment efficacy and safety profiles.
• Discussion of the impact of AOP on neonatal care and outcomes.

Main Results:

• Various treatments exist for AOP, including caffeine citrate, CO2 inhalation, and respiratory support (nCPAP, niPPV), but none are universally established as first-line.
• Effective treatments may carry safety concerns, while conservative measures like kangaroo care may lack efficacy.
• AOP typically resolves with respiratory maturation but complicates neonatal care.

Conclusions:

• There is no definitive gold standard for treating apnea of prematurity.
• Balancing treatment efficacy with safety concerns is crucial in managing AOP.
• Further research is needed to clarify the long-term effects of AOP and its treatments on preterm infants.